Sharp Shalini — SEC Form 4 filings
SEC reporting owner CIK 1377202. 14 Form 4 filings on record with FilingPulse; latest filed 2026-06-30.
Transaction summary — filings shown
Covers all 14 filings on record, filed 2024-01-23 to 2026-06-30. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 1 leg across 1 filing — 1,106 shares, $156,943 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 25.
- Largest priced transaction: sale of 1,106 shares @ $141.90 ($156,943) in NEUROCRINE BIOSCIENCES INC, filed 2024-05-21.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | Director | 5 | — | 1 leg · 1,106 sh · $156,943 | 11 |
| BeOne Medicines Ltd. (ONC) | Director | 3 | — | — | 5 |
| Mirati Therapeutics, Inc. (MRTX) | Director | 1 | — | — | 4 |
| Organon & Co. (OGN) | Director | 3 | — | — | 3 |
| Septerna, Inc. (SEPN) | Director | 2 | — | — | 2 |
Form 4 filings — Sharp Shalini
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-30 | 4 | Septerna, Inc. (SEPN) | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | BeOne Medicines Ltd. (ONC) | Grant/award (A): 18,980 @ $0 | EDGAR |
| 2026-06-15 | 4 | Organon & Co. (OGN) | Grant/award (A): 17,857.14 (derivative) @ $13.44 | EDGAR |
| 2026-05-29 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Grant/award (A): 2,567 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 1,659 @ $0 · Option exercise (M): 1,659 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | Septerna, Inc. (SEPN) | Grant/award (A): 16,623 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Organon & Co. (OGN) | Grant/award (A): 23,904.38 (derivative) @ $10.04 | EDGAR |
| 2025-05-22 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 1,435 @ $0 · Grant/award (A): 1,659 (derivative) @ $0 · Grant/award (A): 3,305 (derivative) @ $0 · Option exercise (M): 1,435 (derivative) @ $0 | EDGAR |
| 2025-05-22 | 4 | BeiGene, Ltd. (BGNE) | Grant/award (A): 10,985 @ $0 · Grant/award (A): 22,750 (derivative) @ $0 | EDGAR |
| 2024-10-02 | 4 | BeiGene, Ltd. (BGNE) | Grant/award (A): 8,151 @ $0 · Grant/award (A): 17,238 (derivative) @ $0 | EDGAR |
| 2024-06-11 | 4 | Organon & Co. (OGN) | Grant/award (A): 9,638.55 (derivative) @ $20.75 | EDGAR |
| 2024-05-23 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Grant/award (A): 1,435 (derivative) @ $0 · Grant/award (A): 2,982 (derivative) @ $0 | EDGAR |
| 2024-05-21 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 2,100 @ $0 · Sale (S): 1,106 @ $141.90 · Option exercise (M): 2,100 (derivative) @ $0 | EDGAR |
| 2024-01-23 | 4 | Mirati Therapeutics, Inc. (MRTX) | Disposition to issuer (D): 4,162 · Disposition to issuer (D): 5,252 · Disposition to issuer (D): 6,808 · Disposition to issuer (D): 7,520 (derivative) | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1377202 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →